This letter responds to the recent Australian survey by Harris and Lee (Australas J Dermatol, 2024, doi: 10.1111/ajd.14361) on the use of oral benzodiazepines for anxiety management in Mohs micrographic surgery (MMS). While commending the authors' efforts, we provide additional perspectives on current practices, recent evidence and safety considerations. We highlight the alignment with U.S. practices, discuss a recent randomized controlled trial supporting diazepam's efficacy and emphasize the importance of non-pharmacological interventions. The letter also addresses the need for flumazenil availability and calls for standardized guidelines and further research to optimize patient care in MMS.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/ajd.14378 | DOI Listing |
J Am Acad Dermatol
December 2024
University of Texas Southwestern Medical Center, 5939 Harry Hines Blvd, 4th Floor, Suite 100, Dallas, Texas, 75390-9191, Department of Dermatology. Electronic address:
J Am Acad Dermatol
December 2024
10000 Sagemore Drive - Suite 10101, Marlton, New Jersey 08053. Electronic address:
J Am Acad Dermatol
December 2024
Epiphany Dermatology, Dallas, Texas; Texas A&M College of Medicine, Dallas, Texas; Department of Dermatology, The University of Texas at Southwestern Medical Center, Dallas, Texas; Division of Dermatology, Baylor Scott & White, Dallas, Texas. Electronic address:
J Dtsch Dermatol Ges
December 2024
Department of Dermatology, University of California Irvine, CA, USA.
Int J Dermatol
December 2024
Division of Dermatology, University of Ottawa, Ottawa, ON, Canada.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!